Bifogade filer
Kurs & Likviditet
Kalender
2025-02-07 | Bokslutskommuniké 2024 |
2024-10-25 | Kvartalsrapport 2024-Q3 |
2024-07-12 | Kvartalsrapport 2024-Q2 |
2024-05-22 | Extra Bolagsstämma 2024 |
2024-04-24 | Kvartalsrapport 2024-Q1 |
2024-04-10 | Ordinarie utdelning EPIS B 0.00 SEK |
2024-04-09 | Årsstämma 2024 |
2024-02-09 | Bokslutskommuniké 2023 |
2023-10-27 | Kvartalsrapport 2023-Q3 |
2023-07-14 | Kvartalsrapport 2023-Q2 |
2023-05-03 | Ordinarie utdelning EPIS B 0.00 SEK |
2023-05-02 | Årsstämma 2023 |
2023-04-28 | Kvartalsrapport 2023-Q1 |
2023-02-17 | Bokslutskommuniké 2022 |
2022-11-16 | Kvartalsrapport 2022-Q3 |
2022-07-15 | Kvartalsrapport 2022-Q2 |
2022-04-29 | Kvartalsrapport 2022-Q1 |
2022-04-05 | Ordinarie utdelning EPIS B 0.00 SEK |
2022-04-04 | Årsstämma 2022 |
2022-02-11 | Bokslutskommuniké 2021 |
2021-10-29 | Kvartalsrapport 2021-Q3 |
2021-07-16 | Kvartalsrapport 2021-Q2 |
2021-05-11 | Ordinarie utdelning EPIS B 0.00 SEK |
2021-05-10 | Årsstämma 2021 |
2021-04-29 | Kvartalsrapport 2021-Q1 |
2021-02-19 | Bokslutskommuniké 2020 |
2020-10-23 | Kvartalsrapport 2020-Q3 |
2020-07-17 | Kvartalsrapport 2020-Q2 |
2020-04-24 | Kvartalsrapport 2020-Q1 |
2020-04-03 | Ordinarie utdelning EPIS B 0.00 SEK |
2020-04-02 | Årsstämma 2020 |
2020-03-10 | Extra Bolagsstämma 2020 |
2020-02-07 | Bokslutskommuniké 2019 |
2019-10-25 | Kvartalsrapport 2019-Q3 |
2019-07-19 | Kvartalsrapport 2019-Q2 |
2019-05-07 | Extra Bolagsstämma 2019 |
2019-04-26 | Kvartalsrapport 2019-Q1 |
2019-04-09 | Ordinarie utdelning EPIS B 0.00 SEK |
2019-04-08 | Årsstämma 2019 |
2019-02-08 | Bokslutskommuniké 2018 |
2018-10-26 | Kvartalsrapport 2018-Q3 |
2018-07-20 | Kvartalsrapport 2018-Q2 |
2018-04-27 | Kvartalsrapport 2018-Q1 |
2018-04-10 | Ordinarie utdelning EPIS B 0.00 SEK |
2018-04-09 | Årsstämma 2018 |
2018-02-23 | Bokslutskommuniké 2017 |
2017-11-10 | Kvartalsrapport 2017-Q3 |
2017-08-18 | Kvartalsrapport 2017-Q2 |
2017-05-23 | Ordinarie utdelning EPIS B 0.00 SEK |
2017-05-22 | Årsstämma 2017 |
2017-05-15 | Kvartalsrapport 2017-Q1 |
2017-02-24 | Bokslutskommuniké 2016 |
2017-02-20 | Extra Bolagsstämma 2017 |
2016-11-04 | Kvartalsrapport 2016-Q3 |
2016-08-19 | Kvartalsrapport 2016-Q2 |
2016-05-25 | Ordinarie utdelning EPIS B 0.00 SEK |
2016-05-24 | Årsstämma 2016 |
2016-05-17 | Kvartalsrapport 2016-Q1 |
2016-02-23 | Bokslutskommuniké 2015 |
2015-11-06 | Kvartalsrapport 2015-Q3 |
2015-08-21 | Kvartalsrapport 2015-Q2 |
2015-05-07 | Ordinarie utdelning EPIS B 0.00 SEK |
2015-05-06 | Kvartalsrapport 2015-Q1 |
2015-05-06 | Årsstämma 2015 |
2015-02-20 | Bokslutskommuniké 2014 |
2014-11-07 | Kvartalsrapport 2014-Q3 |
2014-08-22 | Kvartalsrapport 2014-Q2 |
2014-06-04 | Ordinarie utdelning EPIS B 0.00 SEK |
2014-06-03 | Årsstämma 2014 |
2014-05-09 | Kvartalsrapport 2014-Q1 |
2014-02-21 | Bokslutskommuniké 2013 |
2014-02-12 | Extra Bolagsstämma 2014 |
2013-11-06 | Kvartalsrapport 2013-Q3 |
2013-08-22 | Kvartalsrapport 2013-Q2 |
2013-05-03 | Ordinarie utdelning EPIS B 0.00 SEK |
2013-05-03 | Kvartalsrapport 2013-Q1 |
2013-05-02 | Årsstämma 2013 |
2013-04-03 | Extra Bolagsstämma 2013 |
2013-02-21 | Bokslutskommuniké 2012 |
2012-11-21 | Kvartalsrapport 2012-Q3 |
2012-08-22 | Kvartalsrapport 2012-Q2 |
2012-06-04 | Årsstämma 2012 |
2012-05-04 | Kvartalsrapport 2012-Q1 |
2012-02-21 | Bokslutskommuniké 2011 |
2011-11-21 | Kvartalsrapport 2011-Q3 |
2011-08-22 | Kvartalsrapport 2011-Q2 |
2011-07-20 | Split EPIS B 6:1 |
2011-06-30 | Årsstämma 2011 |
2011-05-21 | Kvartalsrapport 2011-Q1 |
2011-05-13 | Extra Bolagsstämma 2011 |
2011-05-02 | Kvartalsrapport 2011-Q1 |
2011-02-18 | Bokslutskommuniké 2010 |
2010-08-30 | Extra Bolagsstämma 2010 |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
Episurf Medical (NASDAQ: EPIS B) today announces that the company has received 510(k) clearance from the US Food and Drug Administration (FDA) for the Episealer® Patellofemoral System.
The Episealer® Patellofemoral System is an implant system with two opposing implants, intended for patients with osteoarthritis limited to the distal patellofemoral joint in the knee. It is based on Episurf Medical's proprietary individualised implant technology.
Episurf Medical will now prepare for the market launch of the company's first product on the US market.
"Episurf has received US market clearance from the FDA for our patellofemoral implant system. To date, this likely represents the single most significant milestone in the company's history. The company now has access to the largest and most dynamic orthopaedic market in the world and we have come a very long way, indeed, since our first animal investigations nearly 15 years ago. The patellofemoral implant system replaces both sides of the patellofemoral joint of the knee. This means that our technology can now treat not only focal lesions in the cartilage but also overt osteoarthritis. Hence, we can now serve a broader span of indications. As the founder of Episurf, personally, this is a formidable Christmas gift", says Prof. Leif Ryd, Senior Medical Advisor, Episurf Medical.
"Gaining access to the US market symbolises a significant step for any orthopaedic implant manufacturer. For Episurf, this clearance represents somewhat of a double milestone. Firstly, there is the obvious access to the US orthopaedic market, which is of significant size and by far the largest orthopaedic market in the world. However, this clearance represents not only an additional country we are able to sell into, but a new product for the company as well - and our initial entry into treating osteoarthritis as a clinical indication. The patellofemoral joint is one of the higher variance anatomic locations in the musculoskeletal system, and we're confident our individualised technology will be able to play a meaningful role towards advancing care in this area", says Pål Ryfors, CEO Episurf Medical.
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com